| Market Capitalization (Millions $) |
17,988 |
| Shares
Outstanding (Millions) |
181 |
| Employees |
400 |
| Revenues (TTM) (Millions $) |
272 |
| Net Income (TTM) (Millions $) |
-1,013 |
| Cash Flow (TTM) (Millions $) |
-192 |
| Capital Exp. (TTM) (Millions $) |
27 |
Insmed Inc
Insmed Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for patients with unmet medical needs. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed is focused on developing therapies for serious respiratory diseases and rare diseases that have limited treatment options. The company's lead product, ARIKAYCE, is the first and only FDA-approved therapy for patients with Mycobacterium avium complex (MAC) lung disease, a rare and chronic infection that can cause significant damage to the lungs.
The company's pipeline includes several other novel product candidates in various stages of development. INS1007 is being developed for the treatment of non-cystic fibrosis bronchiectasis, a chronic and debilitating respiratory disease. INS1009 is being developed for the treatment of rare pulmonary diseases, including pulmonary alveolar proteinosis and alpha-1 antitrypsin deficiency.
Insmed is also developing therapies for rare diseases outside of the respiratory space. The company's pipeline includes INS1001, a potential treatment for rare genetic disorders, including Pantothenate kinase-associated neurodegeneration (PKAN) and other pantothenate kinase-associated disorders.
The company has a strong commitment to research and development and invests heavily in this area. Insmed has a global team of scientists and researchers who are dedicated to discovering and developing new therapies for patients in need.
Insmed has experienced significant growth in recent years, with a market cap of over $5 billion as of early 202 The company has a strong financial position, with a cash and cash equivalents balance of $499 million as of September 30, 2020.
Overall, Insmed is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for serious respiratory diseases and rare diseases. The company has a strong commitment to research and development and is well-positioned for continued growth and success in the biopharmaceutical industry.
Company Address: 700 US Highway 202/206 Bridgewater 8807 NJ
Company Phone Number: 977-9900 Stock Exchange / Ticker: NASDAQ INSM
|
0.08% 
90.21 %